The University of Warwick Library - WebBridge
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer : ARTemis Trial
Earl,
H. M..
Annals of Oncology.
v.
28.
no.
8.
2017-08-01.
p.
1817 -
1824...
issn:
0923-7534
.
Sorry - based on the information provided, WebBridge cannot offer appropriate links.